Form 4: TG Therapeutics CEO Granted Performance-Based Shares

TG Therapeutics CEO Michael S. Weiss received a grant of 622,000 performance-based restricted shares, vesting upon outperforming the Nasdaq Biotechnology Index.

Summary

• Michael S. Weiss, CEO and Director of TG Therapeutics, Inc. (TGTX), was granted 622,000 restricted shares of common stock.
• The transaction date for this grant was January 8, 2026, with a grant price of $0 per share.
• Following this transaction, Michael S. Weiss beneficially owns a total of 9,778,086 shares of common stock.
• The restricted shares are performance-based, vesting on the first anniversary of the date when TG Therapeutics' Total Shareholder Return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year, 5-year, 7-year, or 9-year period, whichever occurs first.

Sentiment

Score: 7

Explanation: The grant of performance-based restricted shares to the CEO is a positive development as it aligns management's long-term incentives with shareholder value creation by tying vesting to outperforming a key industry index. It's a standard compensation practice, indicating stability rather than a significant new event.

Positives

• The performance-based vesting conditions align management incentives directly with long-term shareholder value creation, requiring the company to outperform a key industry benchmark (Nasdaq Biotechnology Index).
• The grant reinforces the CEO's long-term commitment to the company's strategic success and growth.

Negatives

• The grant of additional shares introduces potential future dilution for existing shareholders, although this is a common aspect of equity compensation.
• The long-term nature of the vesting conditions (up to 9 years) means the incentive may not provide immediate motivation or impact.

Risks

• The vesting of the 622,000 restricted shares is entirely contingent on TG Therapeutics' Total Shareholder Return (TSR) exceeding the Nasdaq Biotechnology Index (NBI) TSR over specified periods, meaning the shares may not vest if these performance targets are not met.

Future Outlook

The vesting conditions for the restricted shares are tied to future performance relative to the Nasdaq Biotechnology Index over 3, 5, 7, or 9-year periods, indicating a long-term strategic focus on achieving superior shareholder return and sustained growth.

Management Comments

• The grant of performance-based restricted shares to CEO Michael S. Weiss aligns his long-term incentives with the company's strategic goal of outperforming the Nasdaq Biotechnology Index, demonstrating a commitment to shareholder value.

Industry Context

Performance-based equity compensation, particularly tied to relative Total Shareholder Return (TSR) against an industry index, is a common and well-regarded practice in the biotechnology and pharmaceutical sectors. This approach incentivizes long-term value creation and aligns executive interests with shareholders, which is crucial given the long development cycles and inherent risks in drug discovery and commercialization.

Comparison to Industry Standards

• The use of Total Shareholder Return (TSR) relative to an industry index like the Nasdaq Biotechnology Index (NBI) is a widely accepted and robust performance metric for executive compensation in the biotech sector, similar to practices seen at companies like Amgen or Gilead Sciences for their long-term incentive plans.
• The multi-year vesting periods (3, 5, 7, or 9 years) are consistent with long-term incentive structures designed to retain key executives and drive sustained performance, mirroring compensation strategies at peer companies focused on drug development and commercialization.

Related Party Transactions

• Grant of 622,000 restricted shares to Michael S. Weiss, the CEO and a Director of TG Therapeutics, Inc., as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential long-term benefit if the company outperforms the NBI, leading to share price appreciation. Minor dilution from the grant, but offset by performance incentives.
• Management/Employees: Increased incentive for the CEO to drive superior performance, potentially fostering a performance-driven culture within the company.

Next Steps

• The company will continue to monitor its Total Shareholder Return (TSR) against the Nasdaq Biotechnology Index (NBI) for the vesting of these restricted shares over the specified performance periods.

Key Dates

Recommendation

This Form 4 filing details a standard executive compensation event—a grant of performance-based restricted shares to the CEO. While it aligns management incentives with long-term shareholder value, it does not introduce new information that would fundamentally alter the investment thesis for TG Therapeutics. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell based solely on this routine disclosure.

Keywords

TG Therapeutics, TGTX, Michael S. Weiss, Restricted Stock Grant, Performance Shares, CEO Compensation, SEC Form 4, Biotechnology, Executive Compensation, Shareholder Return